Stock 9267 GENKY DRUGSTORES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Genky DrugStores Co., Ltd.

Equities

9267

JP3282750003

Market Closed - Japan Exchange
Other stock markets
 07:00:00 02/05/2024 BST 		5-day change 1st Jan Change
5,630 JPY 0.00% Intraday chart for Genky DrugStores Co., Ltd. -2.76% +3.11%
04-30 Genky Drugstores Co., Ltd. Reports Sales Results for the Month and Third Quarter Ended April 2024 CI
04-25 Genky Drugstores Co., Ltd. Provides Dividend Guidance for the Fiscal Year 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.61 for the 2024 fiscal year.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Sales forecast by analysts have been recently revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company does not generate enough profits, which is an alarming weak point.
  • The company is not the most generous with respect to shareholders' compensation.

Ratings chart - Surperformance

Sector: Drug Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
GENKY DRUGSTORES CO., LTD. Stock Genky DrugStores Co., Ltd.
+3.11% 559M -
WALGREENS BOOTS ALLIANCE, INC. Stock Walgreens Boots Alliance, Inc.
-31.79% 15.36B
B-
JD HEALTH INTERNATIONAL INC. Stock JD Health International Inc.
-21.99% 12.45B
B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED Stock Alibaba Health Information Technology Limited
-22.64% 6.75B
B
YIFENG PHARMACY CHAIN CO., LTD. Stock Yifeng Pharmacy Chain Co., Ltd.
+9.74% 6.14B
C
MATSUKIYOCOCOKARA & CO. Stock MatsukiyoCocokara & Co.
-10.91% 6.07B
C+
NAHDI MEDICAL COMPANY Stock Nahdi Medical Company
+0.58% 4.78B
D-
CORPORATIVO FRAGUA, S.A.B. DE C.V. Stock Corporativo Fragua, S.A.B. de C.V.
+59.24% 4.53B -
C
CLICKS GROUP LIMITED Stock Clicks Group Limited
-9.00% 3.81B
B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD. Stock DaShenLin Pharmaceutical Group Co., Ltd.
-12.53% 3.43B
C-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 9267 Stock
  4. Ratings Genky DrugStores Co., Ltd.